(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
1 July 2010 (01.07.2010)

PCT

(10) International Publication Number
WO 2010/075239 A1

(51) **International Patent Classification**:
A61K 31/137 (2006.01) ***A61P 37/06*** (2006.01)
A61P 37/00 (2006.01)

(21) **International Application Number**:
PCT/US2009/068888

(22) **International Filing Date**:
21 December 2009 (21.12.2009)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:

61/139,672	22 December 2008 (22.12.2008)	US
61/218,530	19 June 2009 (19.06.2009)	US
61/246,715	29 September 2009 (29.09.2009)	US

(71) **Applicant** *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) **Inventors; and**
(75) **Inventors/Applicants** *(for US only)*: **SCHMOUDER, Robert** [US/US]; Novartis, One Health Plaza, East Hanover, NJ 07936 (US). **DUMORTIER, Thomas** [BE/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **DAVID, Olivier** [FR/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **LOOBY, Michael** [IE/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH).

(74) **Agent**: **SHIM, Sandra**; Novartis, Patent Department, One Health Plaza, Bldg. 101, East Hanover, NJ 07936 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2010/075239 A1

(54) **Title**: DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST

(57) **Abstract**: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.